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Abstract
Purpose: Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used in the treatment of type 2 diabetes
mellitus in adults, as adjunct to diet and exercise to improve glycemic control. During phase III studies,
sitagliptin was shown to cause toxicity to the pancreas, including pancreatitis. To date there is limited
information available regarding its association with pancreatic carcinoma. Our goal was to qualitatively and
quantitatively review available information in the AERS database in order to provide clinicians with a general
understanding of the comparative occurrence of sitagliptin use and pancreatic carcinoma and any clinically
relevant characteristics that may be useful in identifying patients at risk.
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Purpose
Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used 
in the treatment of type 2 diabetes mellitus in adults, as 
adjunct to diet and exercise to improve glycemic control. 
During phase III studies, sitagliptin was shown to cause 
toxicity to the pancreas, including pancreatitis. To date there 
is limited information available regarding its association with 
pancreatic carcinoma. Our goal was to qualitatively and 
quantitatively review available information in the AERS 
database in order to provide clinicians with a general 
understanding of the comparative occurrence of sitagliptin
use and pancreatic carcinoma and any clinically relevant 
characteristics that may be useful in identifying patients at 
risk.
Methods
We used Empirica Signal software to query AERS from 
November 1968 to December 31, 2013. The software was 
used to calculate a disproportionality statistic, namely the 
Empirical Bayesian Geometric Mean (EBGM), for reports of 
sitagliptin -associated pancreatic carcinoma. The FDA 
considers an EBGM significant if the 5th percentile of the 
distribution is at least two (EB05 > 2.0). With use of a 
disproportionality analysis, sitagliptin was compared with all 
agents listed in AERS. The disproportionality analysis was 
also performed on other medications classified as DPP-4 
inhibitor and other oral hypoglycemic agents.
Results
One hundred cases of pancreatic carcinoma were reported in 
patients who were receiving sitagliptin.   Overall 39% of the 
cases reported in patients receiving treatment with oral 
hypoglycemic agents occurred in patients receiving 
sitagliptin.  An EB05 of 10.3 was determined for sitagliptin
compared to all other agents included in AERS. All but one 
medication classified as a DPP-4 inhibitor were determined 
have an EBO5 > 2.0.  Glimepiride and pioglitazone were also 
determined to have an EBO5 > 2.0, but the findings were not 
consistent within their associated medication classes. 
Conclusions
There appears to be a statistical association between 
sitagliptin use and pancreatic carcinoma. Additional clinical 
studies are needed to further explore this statistical 
association.
Figure 1: DPP-4 Inhibitors and Reports of Pancreatic Carcinoma Table 1: Demographics of Study Population
Variable Study Population (n= 105 )
Mean age 70 years (range: 47-95 years)
Gender 
Female
56%
Duration of therapy
Sitagliptin
460 days
(range: 10- 1947 days)
Reported deaths 28
Figure 2: Oral hypoglycemic agents  and 
Reports of Pancreatic Carcinoma 
